Physician profile
Godehard Oepen
NPI 1508811597
$515,834.24
in general payments reported to CMS, 2019-2025
26 companies · $11K in 2025
The $11K reported for 2025 was more than what 96% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $117K · 2020: $37K · 2021: $80K · 2022: $64K · 2023: $115K · 2024: $92K · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $148K · Consulting Fee: $54K · Travel and Lodging: $11K · Food and Beverage: $5,058 · Education: $79.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $147,633.13 |
| Consulting Fee | $53,938.00 |
| Travel and Lodging | $10,930.24 |
| Food and Beverage | $5,058.16 |
| Education | $79.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $143,068.49 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $117,181.22 | 2019-2024 | Austedo Xr, Austedo, Uzedy |
| Otsuka America Pharmaceutical, INC. | $71,602.02 | 2019-2023 | Rexulti, Abilify Maintena |
| Axsome Therapeutics, INC. | $58,626.93 | 2022-2024 | Auvelity |
| Allergan, INC. | $47,274.40 | 2019-2021 | |
| Alkermes, INC. | $46,476.48 | 2019-2023 | Lybalvi, Aristada |
| Takeda Pharmaceuticals U.S.A., INC. | $18,086.94 | 2019-2023 | Trintellix |
| Vanda Pharmaceuticals INC. | $9,369.57 | 2019-2024 | Fanapt |
| Janssen Pharmaceuticals, INC | $1,003.22 | 2019-2023 | Spravato, Invega Sustenna, Invega Trinza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $897.13 | 2020-2023 | Caplyta |
| Supernus Pharmaceuticals, INC. | $582.86 | 2021-2023 | Qelbree |
| Lundbeck LLC | $313.48 | 2019-2024 | Rexulti, Abilify Maintena |
| Neurocrine Biosciences, INC. | $234.61 | 2022-2023 | Ingrezza |
| Jazz Pharmaceuticals INC. | $200.57 | 2019-2021 | |
| Avanir Pharmaceuticals, INC. | $196.20 | 2019-2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $153.58 | 2019-2021 | |
| Bausch Health US, LLC | $102.79 | 2019-2024 | Wellbutrin, Aplenzin |
| Neuronetics, INC. | $102.28 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $83.53 | 2025 | |
| Almatica Pharma LLC | $82.71 | 2022-2023 | Loreev Xr, Sertraline Hcl |
| Eisai INC. | $68.55 | 2020-2021 | |
| Indivior INC. | $48.54 | 2020-2024 | Perseris |
| Merck Sharp & Dohme LLC | $22.95 | 2021 | |
| Noven Therapeutics, LLC | $20.60 | 2020 | |
| Adlon Therapeutics L.P. | $19.33 | 2019 | |
| Neos Therapeutics, LP | $15.26 | 2023 | Adzenys Xr-Odt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Godehard Oepen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.